Q-omics provides the consensus-scored PDLIM1P4 profile across patient tissues and cancer cell-line models. PDLIM1P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PDLIM1P4 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, PDLIM1P4 RNA expression shows 17,479 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, LIHC, and UVM as cancer lineages where PDLIM1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDLIM1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDLIM1P4 survival associations across molecular data types. PDLIM1P4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDLIM1P4 RNA expression–survival associations across cancer types. High PDLIM1P4 expression shows unfavorable associations in STAD, LUSC, LGG and BLCA, but favorable associations in LAML and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for PDLIM1P4 RNA expression.
This table summarizes PDLIM1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PDLIM1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDLIM1P4 shows lower tumor expression in LIHC, LUSC and LUAD and higher tumor expression in BLCA, THCA and KICH. The LIHC box plot shows higher PDLIM1P4 RNA expression in normal versus tumor tissue (log2 FC = −0.605, t-test p < 0.001).
This table shows molecular features associated with PDLIM1P4 in patient tissues and cancer cell lines. In patient samples, PDLIM1P4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
